Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 245

Similar articles for PubMed (Select 18816591)

1.

Clinical features of late-onset Pompe disease: a prospective cohort study.

Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, Florence JM, Mayhew J, Skrinar A, Corzo D, Laforet P.

Muscle Nerve. 2008 Oct;38(4):1236-45. doi: 10.1002/mus.21025.

PMID:
18816591
2.

Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, Wokke JH.

Neuromuscul Disord. 2009 Feb;19(2):113-7. doi: 10.1016/j.nmd.2008.11.007. Epub 2008 Dec 11.

PMID:
19084399
3.

Use of the muscle volume analyzer to evaluate enzyme replacement therapy in late-onset Pompe disease.

Sugai F, Kokunai Y, Yamamoto Y, Hashida G, Shimazu K, Mihara M, Inoue S, Sakoda S.

J Neurol. 2010 Mar;257(3):461-3. doi: 10.1007/s00415-009-5367-0. Epub 2009 Nov 12.

PMID:
19908083
4.

Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.

Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP.

Neurology. 2009 Jun 2;72(22):1948-52. doi: 10.1212/WNL.0b013e3181a8269b.

PMID:
19487653
5.

A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes.

Van den Berg-Vos RM, Visser J, Kalmijn S, Fischer K, de Visser M, de Jong V, de Haan RJ, Franssen H, Wokke JH, Van den Berg LH.

Arch Neurol. 2009 Jun;66(6):751-7. doi: 10.1001/archneurol.2009.91.

PMID:
19506135
6.

Teaching NeuroImage: Axial muscle atrophy in adult-onset Pompe disease.

Katirji B, Kesner V, Hejal RB, Alshekhlee A.

Neurology. 2008 Mar 4;70(10):e36. doi: 10.1212/01.wnl.0000304251.98684.69. No abstract available.

PMID:
18316684
7.

Motor responses of the sternocleidomastoid muscle in patients with amyotrophic lateral sclerosis.

Pinto S, de Carvalho M.

Muscle Nerve. 2008 Oct;38(4):1312-7. doi: 10.1002/mus.21109.

PMID:
18785186
8.

Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.

Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmüller H, Schoser B.

Neuromuscul Disord. 2007 Oct;17(9-10):698-706. Epub 2007 Jul 23.

PMID:
17643989
9.

Acute progression of neuromuscular findings in infantile Pompe disease.

Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ.

Pediatr Neurol. 2010 Jun;42(6):455-8. doi: 10.1016/j.pediatrneurol.2010.02.006.

PMID:
20472203
10.

[A retrospective study of six patients with late-onset Pompe disease].

Saux A, Laforet P, Pagès AM, Figarella-Branger D, Pellissier JF, Pagès M, Labauge P.

Rev Neurol (Paris). 2008 Apr;164(4):336-42. doi: 10.1016/j.neurol.2007.09.008. French.

PMID:
18439925
11.

Respiratory failure in Pompe disease: treatment with noninvasive ventilation.

Mellies U, Stehling F, Dohna-Schwake C, Ragette R, Teschler H, Voit T.

Neurology. 2005 Apr 26;64(8):1465-7.

PMID:
15851748
12.

Quantitative motor assessment in myotonic dystrophy.

Mathieu J, Boivin H, Richards CL.

Can J Neurol Sci. 2003 May;30(2):129-36.

PMID:
12774952
13.

Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation.

Dubrovsky A, Corderi J, Lin M, Kishnani PS, Jones HN.

Muscle Nerve. 2011 Dec;44(6):897-901. doi: 10.1002/mus.22202. Epub 2011 Sep 26.

PMID:
21953123
14.

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Müller-Felber W, Mengel E, Spranger M, Schoser B.

J Neurol. 2010 Jan;257(1):91-7. doi: 10.1007/s00415-009-5275-3. Epub 2009 Aug 1.

PMID:
19649685
15.

Diagnostic criteria for late-onset (childhood and adult) Pompe disease.

American Association of Neuromuscular & Electrodiagnostic Medicine.

Muscle Nerve. 2009 Jul;40(1):149-60. doi: 10.1002/mus.21393.

PMID:
19533647
16.

Course of disability and respiratory function in untreated late-onset Pompe disease.

Hagemans ML, Hop WJ, Van Doorn PA, Reuser AJ, Van der Ploeg AT.

Neurology. 2006 Feb 28;66(4):581-3.

PMID:
16505317
17.

[Glycogenesis Type II (M. Pompe). Selective failure of the respiratory musculature--a rare first symptom].

Burghaus L, Liu W, Neuen-Jacob E, Gempel K, Haupt WF.

Nervenarzt. 2006 Feb;77(2):181-2, 185-6. German.

PMID:
16228159
18.

Disease severity in children and adults with Pompe disease related to age and disease duration.

Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT.

Neurology. 2005 Jun 28;64(12):2139-41.

PMID:
15985590
19.

Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study.

Lewandowska E, Wierzba-Bobrowicz T, Rola R, Modzelewska J, Stepień T, Lugowska A, Pasennik E, Ryglewicz D.

Folia Neuropathol. 2008;46(2):123-33.

PMID:
18587706
20.

Enzyme replacement therapy for infantile-onset pompe disease: curse or cure?

Willems J, Petros A, Brierley J.

Neurology. 2008 Jul 29;71(5):380-1. doi: 10.1212/01.wnl.0000319722.16673.27. No abstract available.

PMID:
18663187
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk